Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
ID: 357112Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357112

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-203.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-203-Full-Announcement.html
    PAR-25-203.html
    The National Institutes of Health (NIH) has issued a Notice of Funding Opportunity (NOFO) under the National Institute of General Medical Sciences (NIGMS) for focused technology research and development via the R01 grant mechanism. The initiative aims to support projects that develop innovative technologies essential for advancing biomedical research. Eligible projects must already demonstrate proof-of-concept, targeting the creation and validation of working prototypes without addressing specific biological questions. Applications integrated with clinical trials are not permitted and must align with NIGMS's mission of fostering basic research that enhances understanding of biological processes. Key components include specific budget guidelines, eligibility criteria for applicants, and stringent application instructions to ensure compliance. Budgets are not capped but must reflect genuine needs, and the maximum project duration is five years. The review process emphasizes scientific merit and innovation while discouraging incremental technology advancements. Interested applicants are advised to understand the responsive content required for submission, ensuring their project aligns with the NOFO goals. This funding aligns with NIH priorities to develop technologies and methodologies that propel biomedical discoveries, solidifying research capacity across various institutions while fostering diversity and collaboration among scientists.
    Similar Opportunities
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research grants (R21) aimed at developing innovative technologies in biomedical research. This initiative seeks applications that propose high-risk, high-reward projects focused on technology development without existing proof of concept, specifically excluding clinical trials. The funding amount is capped at $275,000 in direct costs over two years, with a maximum of $200,000 available in any single year. Interested applicants, including higher education institutions and nonprofit organizations, must adhere to submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is January 7, 2028.
    Notice of Intent to Publish a Funding Opportunity Announcement: Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at soliciting applications for research focused on developing biomedical technologies that address health disparities. This initiative seeks to support projects that create effective, affordable, and socially acceptable technologies to improve healthcare access and outcomes for underserved populations. The estimated total program funding for this opportunity is $1,200,000, with an expected two awards to be made, and the application process is anticipated to open in late 2025. Interested applicants can reach out to Nichole Daringer at nichole.daringer@nih.gov or call 301-451-4774 for further information.
    NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)" aimed at supporting discrete research projects across various scientific fields, excluding clinical trials. This grant encourages applications from a diverse range of eligible entities, including higher education institutions, nonprofits, and organizations serving underrepresented communities, with the goal of fostering innovative research that enhances public health and scientific knowledge. The funding does not impose limits on application budgets, provided they reflect actual project needs, and allows for a maximum project duration of five years. Interested applicants can find more information and guidelines at the NIH grants website and should direct inquiries to grantsinfo@nih.gov, with the application deadline set for January 7, 2028.
    Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Advancing Bioinformatics, Translational Bioinformatics, and Computational Biology Research initiative, which aims to support innovative research in these fields. This initiative seeks to develop advanced methods and tools that leverage transformative technologies, such as artificial intelligence and machine learning, to enhance the interpretation of complex biological datasets, ultimately improving health outcomes. With an estimated total program funding of $2.5 million and the expectation of awarding approximately 10 grants, interested small businesses are encouraged to prepare their applications, with the anticipated synopsis posting date on October 6, 2025, and a closing date for applications on February 4, 2026. For further inquiries, potential applicants can contact Dr. Catherine Farrell at catherine.farrell@nih.gov or by phone at 301-402-7081.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic and industrial entities to develop innovative solutions for critical health challenges, particularly in the fields of cancer and eye health. The program encourages interdisciplinary research teams to enhance and validate technologies that improve diagnostic methods and treatment capabilities, ultimately supporting better health outcomes for diverse populations. The funding amount is capped at $499,000 annually, with a maximum project duration of five years. Initial submissions are due by January 5, 2025, and interested applicants can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Trailblazer Award aimed at New and Early-Stage Investigators, with a focus on integrating engineering and physical sciences with life and biomedical sciences. This grant opportunity, utilizing the R21 activity code, encourages innovative research projects that may be exploratory, developmental, or high-risk high-impact, and aims to foster collaborations that open new areas of biomedical investigation. Interested applicants, particularly those with expertise in engineering and quantitative sciences, should prepare to submit their applications once the NOFO is officially released, with an estimated synopsis post date of November 21, 2025, and a projected award date of October 1, 2026. For further inquiries, potential applicants can contact Randy King at the National Institute of Biomedical Imaging and Bioengineering via email at Randy.King@nih.gov or by phone at 301-451-0707.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at supporting innovative research in the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, with a focus on advancing medical device technology through collaboration with NIH resources for design, testing, and regulatory support. The initiative is particularly significant as it seeks to accelerate the clinical introduction of medical technologies, ultimately improving patient outcomes while adhering to best practices in research and development. Interested applicants, including various eligible institutions and organizations, must submit their proposals by January 28, 2028, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.